Can-Fite An Emerging NASH Play With CF102
October 13, 2016 at 10:10 AM EDT
On October 13, 2016, Can-Fite Biopharma Ltd (CANF) announced it has submitted the clinical trial protocol for its Phase II study of CF102 in the treatment of NAFLD, the precursor to NASH, to a leading Institutional Review Board (IRB) in Israel.
